Related Experiment Video
Updated: Oct 16, 2025
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
High-Throughput Strategies for the Discovery of Anticancer Drugs by Targeting Transcriptional Reprogramming
Lijun Huang1, Xiaohong Yi1, Xiankuo Yu1
1State Key Laboratory of Southwestern Chinese Medicine Resources, School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Abstract:
Transcriptional reprogramming contributes to the progression and recurrence of cancer. However, the poorly elucidated mechanisms of transcriptional reprogramming in tumors make the development of effective drugs difficult, and gene expression signature is helpful for connecting genetic information and pharmacologic treatment. So far, there are two gene-expression signature-based high-throughput drug discovery approaches: L1000, which measures the mRNA transcript abundance of 978 "landmark" genes, and high-throughput sequencing-based high-throughput screening (HTS2); they are suitable for anticancer drug discovery by targeting transcriptional reprogramming. L1000 uses ligation-mediated amplification and hybridization to Luminex beads and highlights gene expression changes by detecting bead colors and fluorescence intensity of phycoerythrin signal. HTS2 takes advantage of RNA-mediated oligonucleotide annealing, selection, and ligation, high throughput sequencing, to quantify gene expression changes by directly measuring gene sequences. This article summarizes technological principles and applications of L1000 and HTS2, and discusses their advantages and limitations in anticancer drug discovery.
Insights
Two high-throughput drug discovery methods, L1000 and HTS², aid anticancer drug development by analyzing gene expression signatures. These techniques target transcriptional reprogramming in tumors, offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Transcriptional reprogramming drives cancer progression and recurrence.
- Understanding these mechanisms is crucial for developing effective anticancer drugs.
- Gene expression signatures bridge genetic information and pharmacologic treatments.
Purpose of the Study:
- To summarize the technological principles and applications of L1000 and HTS².
- To discuss the advantages and limitations of these methods in anticancer drug discovery.
- To highlight their role in targeting transcriptional reprogramming.
Main Methods:
- L1000 measures mRNA abundance of 978 landmark genes using ligation-mediated amplification and Luminex beads.
- HTS² (High-Throughput Sequencing-based High-Throughput Screening) quantifies gene expression by direct sequencing of RNA molecules.
- Both methods are high-throughput approaches suitable for drug discovery.
Main Results:
- L1000 detects gene expression changes via bead color and fluorescence.
- HTS² utilizes RNA-mediated annealing, selection, ligation, and sequencing for precise quantification.
- Both methods provide valuable gene expression data for drug discovery.
Conclusions:
- L1000 and HTS² are key technologies for anticancer drug discovery targeting transcriptional reprogramming.
- Each method has distinct advantages and limitations influencing its application.
- Further research can optimize these platforms for enhanced therapeutic development.
